Harmony Biosciences Holdings, Inc. HRMY 深 滬
等待開盤 01-13 09:30:00 美东时间
38.27
-0.280
-0.73%
華盛通- 最 高39.40
- 今 開39.39
- 成交量 69.37万股
- 最 低 37.895
- 昨 收 38.55
- 總市值 22.02亿
- 52周最高 40.93
- 市盈率 靜 15.22
- 換手率 1.21%
- 52周最低 25.52
- 委 比 21.77%
- 總股本 5753.26万
- 歷史最高 62.085
- 量 比 1.06
- 振 幅 3.90%
- 歷史最低 18.6112
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harmony Biosciences Hldgs Raises FY2025 Sales Guidance from $845.000M-$865.000M to $868.000M vs $862.659M Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) raises FY2025 sales outlook from $845.000 million-$865.000 million to $868.000 million vs $862.659 million estimate.
01-12 21:19
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Truist Securities Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $45
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.
01-09 01:02
Beacon Biosignals Collaborates With Harmony Biosciences To Incorporate Quantitative EEG Measurements Into Two Of Harmony's Phase 3 Studies Of HBS-301 For Narcolepsy And Idiopathic Hypersomnia
Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and
2025-12-16 19:31
Harmony Biosciences To Highlight New Open-Label Extension Data From Its Investigation Of EPX-100 In Ongoing Phase 3 ARGUS Trial For Treatment Of Dravet Syndrome At 2025 AES Annual Meeting
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS
2025-12-02 21:27
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $42 Price Target
Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $42 price target.
2025-11-24 23:03
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $39
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $36 to $39.
2025-11-07 00:59
